AEON Biopharma to Present at Lake Street’s BIG10 Conference
Event summary
- AEON Biopharma will host 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual BIG10 Conference on September 10, 2026, in New York City.
- The company is advancing ABP-450, a biosimilar to BOTOX®, for full-label U.S. market entry in the $3.0B+ therapeutic neurotoxin market.
- ABP-450 is manufactured by Daewoong Pharmaceutical in an FDA-authorized facility and is currently marketed as Jeuveau® for cosmetic use by Evolus, Inc.
- AEON holds exclusive rights for therapeutic indications of ABP-450 in the U.S., Canada, EU, and UK.
The big picture
AEON Biopharma’s participation in the BIG10 Conference underscores its push to establish ABP-450 as a viable biosimilar in the lucrative U.S. neurotoxin market. The company’s strategy hinges on leveraging its exclusive rights and Daewoong’s manufacturing capabilities to challenge Allergan’s BOTOX® dominance. Success will depend on regulatory clearance and market adoption, particularly as biosimilars gain traction in high-value therapeutic segments.
What we're watching
- Regulatory Approval
- The pace at which AEON secures full-label approval for ABP-450 in the U.S. will determine its competitive positioning against BOTOX®.
- Market Penetration
- Whether AEON can effectively differentiate ABP-450 in the therapeutic neurotoxin market, given its existing cosmetic use as Jeuveau®.
- Investor Sentiment
- How investor meetings at the BIG10 Conference influence AEON’s valuation and access to capital for further development.